Disease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX, USA and Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, OH, USA.
Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, OH, USA.
Acta Biomed. 2022 Mar 14;93(1):e2022026. doi: 10.23750/abm.v93i1.10799.
COVID-19 is now established to be associated with a thrombotic phenomenon, now called COVID-19 associated coagulopathy (CAC). Anti-Endothelial Cell Antibodies (AECA) are a heterogenous group of autoantibodies targeting various endothelial cell antigens or antigens adhering to endothelial cells, They are commonly observed in a variety of auto-immune and rheumatologic conditions, and were observed in patients with the severe acute respiratory syndrome (SARS) in 2005. We aimed to assess AECA status in patients with COVID-19 and their potential contributing role to endothelial injury and CAC. AECA identification was a relatively infrequent finding in COVID-19 patients on admission, and their presence, albeit in only 2/33 patients, was not associated with disease severity. However, as the autoantibodies were only measured at admission, we cannot exclude the possibility of pathogenic AECA developing later in the course of diseaseFurther studies using additional methods are needed to evaluate the presence and potential pathogenic role of AECA in later stages of COVID-19.
新型冠状病毒肺炎（COVID-19）现已被确定与血栓现象有关，现称为 COVID-19 相关凝血障碍（CAC）。抗内皮细胞抗体（AECA）是一组针对各种内皮细胞抗原或粘附在内皮细胞上的抗原的自身抗体，它们在多种自身免疫和风湿性疾病中常见，并在 2005 年严重急性呼吸综合征（SARS）患者中观察到。我们旨在评估 COVID-19 患者的 AECA 状态及其对内皮损伤和 CAC 的潜在作用。入院时 COVID-19 患者的 AECA 鉴定发现相对较少，尽管仅在 33 例患者中的 2 例中存在，但与疾病严重程度无关。然而，由于仅在入院时测量了自身抗体，因此我们不能排除疾病过程中晚期可能会产生致病性 AECA。需要使用其他方法的进一步研究来评估 COVID-19 晚期 AECA 的存在和潜在致病作用。
